BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

276 related articles for article (PubMed ID: 38444070)

  • 1. A systematic review of GLP-1 on anthropometrics, metabolic and endocrine parameters in patients with PCOS.
    Bader S; Bhatti R; Mussa B; Abusanana S
    Womens Health (Lond); 2024; 20():17455057241234530. PubMed ID: 38444070
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The therapeutic effects of glucagon-like peptide-1 receptor agonists and metformin on polycystic ovary syndrome: A protocol for systematic review and meta-analysis.
    Ma R; Ding X; Wang Y; Deng Y; Sun A
    Medicine (Baltimore); 2021 Jun; 100(23):e26295. PubMed ID: 34115034
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Canagliflozin combined with metformin versus metformin monotherapy for endocrine and metabolic profiles in overweight and obese women with polycystic ovary syndrome: A single-center, open-labeled prospective randomized controlled trial.
    Zhang J; Xing C; Cheng X; He B
    Front Endocrinol (Lausanne); 2022; 13():1003238. PubMed ID: 36147577
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of glucagon-like peptide-1 in reproduction: from physiology to therapeutic perspective.
    Jensterle M; Janez A; Fliers E; DeVries JH; Vrtacnik-Bokal E; Siegelaar SE
    Hum Reprod Update; 2019 Jul; 25(4):504-517. PubMed ID: 31260047
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists in the Treatment of Obese Women with Polycystic Ovary Syndrome.
    Tzotzas T; Karras SN; Katsiki N
    Curr Vasc Pharmacol; 2017; 15(3):218-229. PubMed ID: 28003008
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Insulin Sensitizers for Improving the Endocrine and Metabolic Profile in Overweight Women With PCOS.
    Xing C; Li C; He B
    J Clin Endocrinol Metab; 2020 Sep; 105(9):2950-63. PubMed ID: 32490533
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Obesity, Polycystic Ovary Syndrome, and Infertility: A New Avenue for GLP-1 Receptor Agonists.
    Cena H; Chiovato L; Nappi RE
    J Clin Endocrinol Metab; 2020 Aug; 105(8):e2695-709. PubMed ID: 32442310
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects and plasma proteomic analysis of GLP-1RA versus CPA/EE, in combination with metformin, on overweight PCOS women: a randomized controlled trial.
    Liao M; Li X; Zhang H; Zhou L; Shi L; Li W; Shen R; Peng G; Zhao H; Shao J; Wang X; Sun Z; Zheng H; Long M
    Endocrine; 2024 Jan; 83(1):227-241. PubMed ID: 37653215
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Short-term combined treatment with exenatide and metformin for overweight/obese women with polycystic ovary syndrome.
    Ma RL; Deng Y; Wang YF; Zhu SY; Ding XS; Sun AJ
    Chin Med J (Engl); 2021 Nov; 134(23):2882-2889. PubMed ID: 34732660
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Liraglutide and polycystic ovary syndrome: is it only a matter of body weight?
    Pugliese G; de Alteriis G; Muscogiuri G; Barrea L; Verde L; Zumbolo F; Colao A; Savastano S
    J Endocrinol Invest; 2023 Sep; 46(9):1761-1774. PubMed ID: 37093453
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Metformin and lifestyle modification in polycystic ovary syndrome: systematic review and meta-analysis.
    Naderpoor N; Shorakae S; de Courten B; Misso ML; Moran LJ; Teede HJ
    Hum Reprod Update; 2015; 21(5):560-74. PubMed ID: 26060208
    [TBL] [Abstract][Full Text] [Related]  

  • 12. AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS, AMERICAN COLLEGE OF ENDOCRINOLOGY, AND ANDROGEN EXCESS AND PCOS SOCIETY DISEASE STATE CLINICAL REVIEW: GUIDE TO THE BEST PRACTICES IN THE EVALUATION AND TREATMENT OF POLYCYSTIC OVARY SYNDROME--PART 1.
    Goodman NF; Cobin RH; Futterweit W; Glueck JS; Legro RS; Carmina E; ; ;
    Endocr Pract; 2015 Nov; 21(11):1291-300. PubMed ID: 26509855
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Short-term effect of beinaglutide combined with metformin versus metformin alone on weight loss and metabolic profiles in obese patients with polycystic ovary syndrome: a pilot randomized trial.
    Wen Q; Fang S; Liang Y; Tian Y; Chen Y; Yuan J; Chen Q
    Front Endocrinol (Lausanne); 2023; 14():1156521. PubMed ID: 37347114
    [TBL] [Abstract][Full Text] [Related]  

  • 14. GLP-1 receptor agonists versus metformin in PCOS: a systematic review and meta-analysis.
    Han Y; Li Y; He B
    Reprod Biomed Online; 2019 Aug; 39(2):332-342. PubMed ID: 31229399
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Role of Glp-1 Receptor Agonists in Insulin Resistance with Concomitant Obesity Treatment in Polycystic Ovary Syndrome.
    Bednarz K; Kowalczyk K; Cwynar M; Czapla D; Czarkowski W; Kmita D; Nowak A; Madej P
    Int J Mol Sci; 2022 Apr; 23(8):. PubMed ID: 35457152
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Effect of Oral Antidiabetic Drugs on Improving the Endocrine and Metabolic States in Women with Polycystic Ovary Syndrome: A Systematic Review and Network Meta-analysis.
    Yang S; Zhao L; He W; Mi Y
    Drugs; 2022 Sep; 82(14):1469-1480. PubMed ID: 36129662
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A 12-week treatment with the long-acting glucagon-like peptide 1 receptor agonist liraglutide leads to significant weight loss in a subset of obese women with newly diagnosed polycystic ovary syndrome.
    Jensterle M; Kravos NA; Pfeifer M; Kocjan T; Janez A
    Hormones (Athens); 2015; 14(1):81-90. PubMed ID: 25885106
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Liraglutide: New Perspectives for the Treatment of Polycystic Ovary Syndrome.
    Papaetis GS; Filippou PK; Constantinidou KG; Stylianou CS
    Clin Drug Investig; 2020 Aug; 40(8):695-713. PubMed ID: 32583294
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of single and combined treatment with exenatide and metformin on menstrual cyclicity in overweight women with polycystic ovary syndrome.
    Elkind-Hirsch K; Marrioneaux O; Bhushan M; Vernor D; Bhushan R
    J Clin Endocrinol Metab; 2008 Jul; 93(7):2670-8. PubMed ID: 18460557
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of long-term treatment with metformin added to hypocaloric diet on body composition, fat distribution, and androgen and insulin levels in abdominally obese women with and without the polycystic ovary syndrome.
    Pasquali R; Gambineri A; Biscotti D; Vicennati V; Gagliardi L; Colitta D; Fiorini S; Cognigni GE; Filicori M; Morselli-Labate AM
    J Clin Endocrinol Metab; 2000 Aug; 85(8):2767-74. PubMed ID: 10946879
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.